Get trade alerts

Dyne Therapeutics ($DYN) Insider Trading & Smart Money Activity

Dyne Therapeutics, Inc. · Biotechnology · Latest filing Oct 2, 2026

Dyne Therapeutics, Inc. ($DYN) has 14 insider trades and 2 13F position changes on file. In the last 12 months on the open market, 1 insider bought ($40K) and 6 insiders sold ($22.88M), net -$22.84M.

Insider buyers (12 mo)
1
Insider sellers (12 mo)
6
Net insider $ (12 mo)
-$22.84M
Congress trades (12 mo)
0
13F moves on file
2
Analyst ratings on file
0

DYN insider buying and selling by quarter

QuarterInsider buysInsider salesCongress buys / sales13F added / cut
Q1 2026 0 0 0 / 0 0 / 0
Q2 2026 0 12 · $22.88M 0 / 0 2 / 0
Q3 2026 0 0 0 / 0 0 / 0
Q4 2026 1 · $40K 0 0 / 0 0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All DYN insider, congress, 13F and analyst activity

DateSourceWhoActionSharesValue / amount ΔOwn1W1M6MFilingStory
Insider Posner Brian SDirector Buy (Open-market buy) 2.50K sh $40K +9.5% —
Insider Jason Rhodes Sell (Open-market sale) 10b5-1 195.43K sh $4.13M +7.4%+18.1% —
Insider Jason Rhodes Sell (Open-market sale) 10b5-1 309.27K sh $6.58M +9.1%+22.4% Read
Insider Jason Rhodes Sell (Open-market sale) 10b5-1 24.10K sh $508.51K +11.9%+24.4% Read
Insider Erick LuceraChief Financial Officer Sell (Open-market sale) 2.36K sh $48.11K +11.9%+24.4% Read
Insider Jason Rhodes Sell (Open-market sale) 10b5-1 95.90K sh $2.02M +7.2%+20.2% Read
Insider Jason Rhodes Sell (Open-market sale) 10b5-1 147.76K sh $3.12M +9.6%+17.9% Read
Insider Dirk Kersten Sell (Open-market sale) 10b5-1 73.29K sh $1.54M +9.6%+17.9% —
Insider Dirk Kersten Sell (Open-market sale) 10b5-1 190.68K sh $3.92M +1.9%+11.2% Read
Insider Barry Greene Buy (Grant or award) 57.46K sh +1.9%+11.2% —
Insider Dirk Kersten Sell (Open-market sale) 10b5-1 46.90K sh $941.30K +4.1%+18.4% Read
Insider Douglas KerrChief Medical Officer Sell (Open-market sale) 10b5-1 887 sh $16.26K +12.1%+25.7% —
Insider Johanna Friedl-NadererChief Commercial Officer Sell (Open-market sale) 10b5-1 145 sh $2.66K +12.1%+25.7% —
Insider John CoxCEO & President Sell (Open-market sale) 10b5-1 2.68K sh $49.18K +12.1%+25.7% —
13F T. Rowe Price Investment Management Added +13.25M sh $683.75M +0.5%+8.3% —
13F T. Rowe Price Investment Management Added +13.25M sh $552.61M +0.5%+8.3% —

1W / 1M / 6M = how DYN moved from the trade or filing date.

Insider trading in DYN: who is buying and selling

InsiderRoleTradesOpen-market netShares heldLast trade
Posner Brian S Director 1 +$40K Oct 2, 2026
Jason Rhodes 5 -$16.36M Jun 29, 2026
Erick Lucera Chief Financial Officer 1 -$48.11K Jun 25, 2026
Dirk Kersten 3 -$6.41M Jun 23, 2026
Barry Greene 1 — Jun 22, 2026
Douglas Kerr Chief Medical Officer 1 -$16.26K Jun 16, 2026
Johanna Friedl-Naderer Chief Commercial Officer 1 -$2.66K Jun 16, 2026
John Cox CEO & President 1 -$49.18K Jun 16, 2026

Institutions moving DYN (13F)

Frequently asked questions

Are DYN insiders buying or selling?

Over the last 12 months 1 insider made 1 open-market purchase worth $40K and 6 insiders made 12 open-market sales worth $22.88M, a net -$22.84M.

What is the latest insider trade in DYN?

Posner Brian S, Director filed a buy (open-market buy) of 2.50K sh worth $40K on Oct 2, 2026.

Which institutions changed their DYN positions?

Recent 13F filers moving the stock include T. Rowe Price Investment Management.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text